Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 2
2005 1
2006 2
2007 2
2008 7
2009 13
2010 10
2011 13
2012 18
2013 21
2014 16
2015 21
2016 29
2017 13
2018 12
2019 13
2020 11
2021 17
2022 14
2023 12
2024 8
2025 8
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Swedberg K, et al. Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Lancet. 2010. PMID: 20801500 Clinical Trial.
FINDINGS: 6558 patients were randomly assigned to treatment groups (3268 ivabradine, 3290 placebo). Data were available for analysis for 3241 patients in the ivabradine group and 3264 patients allocated placebo. ...Fewer serious adverse events occurred in the iva …
FINDINGS: 6558 patients were randomly assigned to treatment groups (3268 ivabradine, 3290 placebo). Data were available for analysis …
Ivabradine as adjuvant treatment for chronic heart failure.
Benstoem C, Kalvelage C, Breuer T, Heussen N, Marx G, Stoppe C, Brandenburg V. Benstoem C, et al. Cochrane Database Syst Rev. 2020 Nov 4;11(11):CD013004. doi: 10.1002/14651858.CD013004.pub2. Cochrane Database Syst Rev. 2020. PMID: 33147368 Free PMC article.
OBJECTIVES: To assess the effectiveness and safety of ivabradine in individuals with chronic heart failure. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, and CPCI-S Web of Science in March 2020. ...We were able to perform two meta-analyses focusing on participants …
OBJECTIVES: To assess the effectiveness and safety of ivabradine in individuals with chronic heart failure. SEARCH METHODS: We search …
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.
Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Taub PR, et al. J Am Coll Cardiol. 2021 Feb 23;77(7):861-871. doi: 10.1016/j.jacc.2020.12.029. J Am Coll Cardiol. 2021. PMID: 33602468 Free article. Clinical Trial.
METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were …
METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controll …
Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
Wang Z, Wang W, Li H, Zhang A, Han Y, Wang J, Hou Y. Wang Z, et al. J Cardiovasc Pharmacol. 2022 Apr 1;79(4):549-557. doi: 10.1097/FJC.0000000000001209. J Cardiovasc Pharmacol. 2022. PMID: 34983905
Furthermore, ivabradine may reduce the ventricular rate in patients with AF. In conclusion, we found that both large and small cumulative doses of ivabradine were associated with an increased incidence of AF, and the effect was more marked in the LVEF >40% subgro …
Furthermore, ivabradine may reduce the ventricular rate in patients with AF. In conclusion, we found that both large and small cumula …
Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients.
Calabrò LA, Pasetto M, Scolletta S, Annoni F, Demailly Z, Halenarova K, Donadello K, Taccone FS. Calabrò LA, et al. BMC Anesthesiol. 2025 May 30;25(1):276. doi: 10.1186/s12871-025-03121-y. BMC Anesthesiol. 2025. PMID: 40448257 Free PMC article.
CONCLUSIONS: Ivabradine may be a useful alternative to beta-blocker in the management of inappropriate sinus tachycardia. ...Larger randomized trials are needed to investigate the potential benefits or hazards of ivabradine use on hemodynamics and long-term outcomes …
CONCLUSIONS: Ivabradine may be a useful alternative to beta-blocker in the management of inappropriate sinus tachycardia. ...Larger r …
Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
Marciniak TA, Atar D, Serebruany V. Marciniak TA, et al. Am J Med. 2020 Mar;133(3):347-351. doi: 10.1016/j.amjmed.2019.07.046. Epub 2019 Aug 20. Am J Med. 2020. PMID: 31442391
BACKGROUND: Ivabradine, a heart rate-slowing drug used to treat heart failure and (in Europe) angina, had varying impacts upon cardiovascular events in its 3 large outcome trials. ...CONCLUSION: Ivabradine used concomitantly with a loop diuretic has a beneficial imp …
BACKGROUND: Ivabradine, a heart rate-slowing drug used to treat heart failure and (in Europe) angina, had varying impacts upon cardio …
Ivabradine in Patients Undergoing Noncardiac Surgery: A Randomized Controlled Trial.
Szczeklik W, Fronczek J, Putowski Z, Włudarczyk A, Górka J, Seczyńska B, Gryszówka D, Widawska A, Białka S, Palaczyński P, Borys M, Kutnik P, Czarnik T, Szczepańska A, Możański M, Mieszkowski M, Kotfis K, Trzebicki J, Sadowski Ł, Sołek-Pastuszka J, Grudzień P, Mudyna W, Misiewska-Kaczur A, Owczuk R, Kudliński B, Studzińska D, Pawlik J, Makowski A, Ziętkiewicz M, Przydacz M, Goździk W, Gola W, Jasiewicz P, Zhao Z, Shyr Y, Devereaux PJ; PERI-CRIT Investigators. Szczeklik W, et al. Circulation. 2025 Oct 21;152(16):1126-1135. doi: 10.1161/CIRCULATIONAHA.125.076704. Epub 2025 Aug 30. Circulation. 2025. PMID: 40884771 Clinical Trial.
MINS occurred in 178 of 1050 patients (17.0%) in the ivabradine group and in 159 of 1051 patients (15.1%) in the placebo group (relative risk, 1.12 [95% CI, 0.92 to 1.37]; P=0.25). ...CONCLUSIONS: Among patients undergoing noncardiac surgery, ivabradine did not redu …
MINS occurred in 178 of 1050 patients (17.0%) in the ivabradine group and in 159 of 1051 patients (15.1%) in the placebo group (relat …
Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z. Pei H, et al. Int Heart J. 2019 Jul 27;60(4):899-909. doi: 10.1536/ihj.18-559. Epub 2019 Jul 12. Int Heart J. 2019. PMID: 31308326 Free article.
Safety analysis showed no significant difference in the RR of severe adverse events between the ivabradine group and the standard anti-heart failure treatment group (P = 0.40). However, ivabradine significantly increased the RR of visual symptoms in CHF patients (RR …
Safety analysis showed no significant difference in the RR of severe adverse events between the ivabradine group and the standard ant …
Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis.
Maagaard M, Nielsen EE, Sethi NJ, Liang N, Yang SH, Gluud C, Jakobsen JC. Maagaard M, et al. BMJ Evid Based Med. 2022 Aug;27(4):224-234. doi: 10.1136/bmjebm-2021-111724. Epub 2021 Nov 17. BMJ Evid Based Med. 2022. PMID: 34789473 Free PMC article.
Meta-analysis showed no evidence of a difference between ivabradine and control when assessing cardiovascular mortality and myocardial infarction. Ivabradine seemed to increase the risk of non-serious adverse events. CONCLUSION AND RELEVANCE: High certainty evidence …
Meta-analysis showed no evidence of a difference between ivabradine and control when assessing cardiovascular mortality and myocardia …
Ivabradine has a neutral effect on mortality in randomized controlled trials.
Kang S, Li CJ, Zhang XM. Kang S, et al. Medicine (Baltimore). 2017 Oct;96(40):e8067. doi: 10.1097/MD.0000000000008067. Medicine (Baltimore). 2017. PMID: 28984762 Free PMC article. Review.
The study was aimed to investigate whether ivabradine would reduce more RHR, cardiovascular disease (CVD) mortality, and all-cause mortality than those placebo or beta-blockers. METHODS: The authors performed a meta-analysis of 8 randomized controlled clinical studies (wit …
The study was aimed to investigate whether ivabradine would reduce more RHR, cardiovascular disease (CVD) mortality, and all-cause mo …
235 results